Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer.
Adoptive therapy
Immunotherapy
Non–small cell lung cancer
T cells
Targeted therapy
Journal
Surgical oncology clinics of North America
ISSN: 1558-5042
Titre abrégé: Surg Oncol Clin N Am
Pays: United States
ID NLM: 9211789
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
entrez:
5
9
2020
pubmed:
5
9
2020
medline:
13
8
2021
Statut:
ppublish
Résumé
Immunotherapy, targeted therapy, and adoptive T-cell therapy have been revolutionary advancements in cancer research. Some of these therapies have become the standard of care for lung cancer and replaced older treatment algorithms; some continue to be studied in clinical trials. This article discusses the current state of novel treatment options for non-small cell lung cancer patients with metastatic and locoregional disease, with focus on immunotherapy, targeted therapy, and adoptive T-cell therapy.
Identifiants
pubmed: 32883458
pii: S1055-3207(20)30049-1
doi: 10.1016/j.soc.2020.06.009
pmc: PMC7388816
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
555-569Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure B. Sepesi receives consultant fees from Bristol-Myers Squibb and research funding from Rexanna Foundation. T. Cascone reports speaker’s fees from the Society for Immunotherapy of Cancer and Bristol-Myers Squibb, consulting fees MedImmune/Astra Zeneca and Bristol-Myers Squibb, and advisory role fees from EMD Serono and Bristol-Myers Squibb. S.G. Chun is on the advisory board and receives consultant fees from Astra Zeneca. M. Altan receives advisory fees from GlaxoSmithKline and Shattuck Labs and research funding from Genentech, Nektar Therapeutics, Merck, GlaxoSmithKline, Novartis, Jounce Therapeutics, Bristol-Myers Squibb, Eli Lilly, and Adaptimmune. X. Le receives consultant and advisory fees from Eli Lilly, Astra Zeneca, and EMD Serono and research funds from Eli Lilly and Boehringer Ingelheim.
Références
N Engl J Med. 2017 Nov 16;377(20):1919-1929
pubmed: 28885881
Clin Cancer Res. 2015 Dec 15;21(24):5439-44
pubmed: 26672084
Cancer Discov. 2020 Feb;10(2):185-197
pubmed: 31974169
Expert Rev Respir Med. 2020 Feb;14(2):125-136
pubmed: 31829747
Nat Rev Clin Oncol. 2011 Aug 02;8(10):577-85
pubmed: 21808266
N Engl J Med. 2009 Sep 3;361(10):947-57
pubmed: 19692680
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
J Hematol Oncol. 2019 Dec 18;12(1):139
pubmed: 31852498
Clin Lung Cancer. 2018 Jul;19(4):e533-e536
pubmed: 29789220
Science. 2002 Oct 25;298(5594):850-4
pubmed: 12242449
Genome Res. 2012 Mar;22(3):436-45
pubmed: 22194472
N Engl J Med. 1988 Dec 22;319(25):1676-80
pubmed: 3264384
Cancer Discov. 2014 Sep;4(9):1046-61
pubmed: 24893891
N Engl J Med. 2018 Aug 30;379(9):e14
pubmed: 30157404
J Clin Oncol. 2011 Mar 1;29(7):917-24
pubmed: 21282551
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Blood. 2018 Jun 14;131(24):2621-2629
pubmed: 29728402
Clin Cancer Res. 2015 Mar 1;21(5):1019-27
pubmed: 25538264
Curr Oncol Rep. 2019 Feb 26;21(3):21
pubmed: 30806814
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
N Engl J Med. 2010 Oct 28;363(18):1727-33
pubmed: 20979472
Front Immunol. 2019 Oct 11;10:2250
pubmed: 31681259
J Clin Oncol. 2017 Aug 10;35(23):2613-2618
pubmed: 28520527
J Thorac Oncol. 2016 Nov;11(11):2027-2032
pubmed: 27544060
J Thorac Oncol. 2019 Apr;14(4):691-700
pubmed: 30599201
N Engl J Med. 2015 Apr 30;372(18):1689-99
pubmed: 25923549
N Engl J Med. 2018 Jan 11;378(2):113-125
pubmed: 29151359
Am Soc Clin Oncol Educ Book. 2016;35:e450-8
pubmed: 27249753
J Thorac Oncol. 2018 Oct;13(10):1530-1538
pubmed: 29935304
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
pubmed: 15329413
Lancet. 2017 Jul 1;390(10089):3-4
pubmed: 28501139
J Clin Oncol. 2013 Sep 20;31(27):3327-34
pubmed: 23816960
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Cell. 2015 Apr 9;161(2):205-14
pubmed: 25860605
Nat Med. 2012 Feb 12;18(3):382-4
pubmed: 22327622
Sci China Life Sci. 2016 May;59(5):468-79
pubmed: 26968708
N Engl J Med. 2018 Feb 22;378(8):731-739
pubmed: 29466156
Science. 2015 Oct 16;350(6258):aab4077
pubmed: 26405231
Cancer J. 2012 Mar-Apr;18(2):160-75
pubmed: 22453018
J Clin Oncol. 2015 Dec 1;33(34):4007-14
pubmed: 26324372
Mol Oncol. 2015 Dec;9(10):1918-35
pubmed: 26578452
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Lancet Oncol. 2016 Feb;17(2):234-242
pubmed: 26708155
N Engl J Med. 2014 Jun 26;370(26):2537-9
pubmed: 24963575
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Nat Biotechnol. 2013 Jan;31(1):71-5
pubmed: 23242161
J Clin Oncol. 2016 Mar 1;34(7):721-30
pubmed: 26729443
Science. 2004 Jun 4;304(5676):1497-500
pubmed: 15118125
Lancet Oncol. 2018 Jan;19(1):139-148
pubmed: 29174310
Am Soc Clin Oncol Educ Book. 2019 Jan;39:e70-e78
pubmed: 31099621
Lancet Oncol. 2017 Dec;18(12):1590-1599
pubmed: 29074098
Cancer Res. 2005 Aug 15;65(16):7096-101
pubmed: 16103058
J Clin Oncol. 2019 Jun 1;37(16):1370-1379
pubmed: 30892989
N Engl J Med. 2017 Oct 5;377(14):1345-1356
pubmed: 28889792
J Immunother Cancer. 2018 Jul 17;6(1):75
pubmed: 30012210
J Clin Oncol. 2016 Jul 10;34(20):2389-97
pubmed: 27217459
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
JAMA Oncol. 2018 Jan 11;4(1):e173501
pubmed: 28973074
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
N Engl J Med. 2016 Jan 7;374(1):54-61
pubmed: 26698910
Nature. 2007 Aug 2;448(7153):561-6
pubmed: 17625570
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
J Thorac Oncol. 2020 May;15(5):816-826
pubmed: 32036071
Lancet Oncol. 2019 Jul;20(7):924-937
pubmed: 31122901
Lancet Oncol. 2016 Jul;17(7):984-993
pubmed: 27283860
Lancet Oncol. 2016 Dec;17(12):1672-1682
pubmed: 27789196
Clin Cancer Res. 2013 Sep 1;19(17):4792-800
pubmed: 23690483
Ann Oncol. 2019 Jul 1;30(7):1121-1126
pubmed: 30980071
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Immunother. 2013 Feb;36(2):133-51
pubmed: 23377668
N Engl J Med. 2004 May 20;350(21):2129-39
pubmed: 15118073
Cancer Discov. 2015 Aug;5(8):842-9
pubmed: 25971939
J Immunother Cancer. 2019 Oct 24;7(1):276
pubmed: 31651363
Blood. 2013 Aug 8;122(6):863-71
pubmed: 23770775
Lancet Oncol. 2019 Dec;20(12):1691-1701
pubmed: 31669155
J Clin Oncol. 2008 Nov 10;26(32):5233-9
pubmed: 18809613
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977